As the concentration range where 2DG can increase the IFN-γ secretion is achievable in vivo, low-dose 2DG as an adjuvant could potentially increase IFN-γ secretion in the context of anti-tumor immunity. The gene discussed is IFNG; the disease is neoplasm.